We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GLENMARK, INVAGEN BEGIN JOINT GENERICS VENTURE

GLENMARK, INVAGEN BEGIN JOINT GENERICS VENTURE

December 27, 2005

Indian drug firm Glenmark Pharmaceuticals has signed a deal with U.S.-based InvaGen to market generic versions of seven brand drugs with a current annual U.S. market of $4.1 billion, in Glenmark's latest move to bolster its position in the U.S. market.

Glenmark has cut deals with a number of U.S.-based drugmakers to tap the U.S. generics market, partly by acquiring or licensing rights to already-approved generic drugs. Glenmark is poised to "close FY 2006 with a portfolio of roughly 20 ANDAs [abbreviated new drug applications] filed during the year," the company said.

InvaGen and Glenmark will jointly develop and market a combination of patent-protected and off-patent drugs and split all costs and profits, Glenmark said, but did not indicate what drugs the partners plan to market. InvaGen will develop and license the drugs to Glenmark, as well as file generic drug applications with the FDA, while Glenmark will obtain U.S. regulatory approvals. One application has been filed and three more should be filed by March 2006, Glenmark said.

Earlier this year, Glenmark and InvaGen agreed to jointly market a generic version of Bristol-Myers Squibb's hypertension drug Monopril (fosinopril sodium). Glenmark this year also purchased two ANDAs from Irish drugmaker Clonmel, licensed generic naproxen and generic nitroglycerin from U.S. drug firms Interpharm and Konec, respectively, and agreed to collaborate with Indian drugmaker Shasun on 13 generic products for the U.S. market.

KEYWORDS FDAnews Drug Daily Bulletin

    Upcoming Events

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • EMA Expands Review of GLP-1 Agonists and Suicide, While Weight Loss Drug Market Looks to Expand

    • FDA Urges Avoiding Plastic Syringes Made in China Due to Device Failures

    • FDA Laboratory-Developed Tests Proposal Comments Pour In by Thousands

    • Healthcare Titans Expand Their Portfolios in Acquisition Deals

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing